Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%

Quince Therapeutics, Inc.

Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.
All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.
Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.
8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).
LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.